KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

DIALON 500 MG TABLETS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

500 MG

 

GENERIC NAME:

METFORMIN HYDROCHLORIDE

 

MANUFACTURER:

JULPHAR

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

C

 

INDICATIONS:

Diabetes mellitus

 

SIDE EFFECTS:

Anemia, megaloblastic

hypoglycemia

lactic acidosis

Anorexia

diarrhea

dyspepsia

flatulence

headache

metallic taste

nausea

vomiting

weight loss

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

>> Intestinal obstruction

>> Vomiting

>> Other conditions causing delayed food absorption

>> Hyperglycemia-causing conditions

Female hormonal changes

Fever, high

Hypercortisolism, not optimally treated

Psychological stress

>> Hyperthyroidism, not optimally controlled

>> Hypoglycemia-causing conditions

Adrenal insufficiency, not optimally controlled

Debilitated physical condition

Malnutrition

Pituitary insufficiency, not optimally controlled

>> Hypothyroidism, not optimally controlled

>> Diarrhea

>> Gastroparesis

 

ADULT DOSE:

Antihyperglycemic agent- As monotherapy- Initial-Oral, 500 mg two times a day, taken with morning and evening meals. The daily dose may be increased by 500 mg at weekly intervals as needed. An alternative dose is 850 mg a day, taken with the morning meal. The daily dose may be increased by 850 mg at fourteen-day intervals. Maintenance-Oral, 500 or 850 mg two to three times a day, taken with meals. In combination with a sulfonylurea- The dosage of each agent must be adjusted until the desired degree of glycemic control is achieved. In combination with insulin - Oral, initially 500 mg a day. The dosage may be increased by 500 mg at weekly intervals as needed. Note: The current insulin dose should be continued upon initiation of metformin therapy. However, the insulin dose should be decreased by 10 to 25% when the fasting plasma glucose concentration decreases to less than 120 mg per dL (6.7 mmol per L).

 

MAXIMUM ADULT DOSE:

2550 mg a day.

 

PEDIATRIC DOSE:

Safety and efficacy have not been established.  

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Antihyperglycemic agent- As monotherapy- Initial-Oral, 500 mg two times a day, taken with morning and evening meals. The daily dose may be increased by 500 mg at weekly intervals as needed. An alternative dose is 850 mg a day, taken with the morning meal. The daily dose may be increased by 850 mg at fourteen-day intervals. Maintenance-Oral, 500 or 850 mg two to three times a day, taken with meals. In combination with a sulfonylurea- The dosage of each agent must be adjusted until the desired degree of glycemic control is achieved. In combination with insulin - Oral, initially 500 mg a day. The dosage may be increased by 500 mg at weekly intervals as needed. Note: The current insulin dose should be continued upon initiation of metformin therapy. However, the insulin dose should be decreased by 10 to 25% when the fasting plasma glucose concentration decreases to less than 120 mg per dL (6.7 mmol per L).

 

 

PREVIOUS

  

NEXT